King's College London

Research portal

Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts

Research output: Contribution to journalReview article

Rengaswamy Sankaranarayanan, Partha Basu, Prabhdeep Kaur, Rajesh Bhaskar, Gurinder Bir Singh, Phumzay Denzongpa, Rajesh K. Grover, Paul Sebastian, Tapan Saikia, Kunal Oswal, Rishav Kanodia, Amantia Dsouza, Ravi Mehrotra, Goura Kishor Rath, Viniita Jaggi, Sundram Kashyap, Ishu Kataria, Roopa Hariprasad, Peter Sasieni, Neerja Bhatla & 4 more Preetha Rajaraman, Edward L. Trimble, Soumya Swaminathan, Arnie Purushotham

Original languageEnglish
Pages (from-to)e637-e644
JournalThe Lancet Oncology
Issue number11
Publication statusPublished - 1 Nov 2019

King's Authors


Efforts are being made to scale up human papillomavirus (HPV) vaccination for adolescent girls in India. Bivalent and quadrivalent HPV vaccines were licensed in the country in 2008, and a nonavalent vaccine was licensed in 2018. Demonstration projects initiated in Andhra Pradesh and Gujarat in 2009 introduced HPV vaccination in public health services in India. Following a few deaths in these projects, although subsequently deemed unrelated to vaccination, HPV vaccination in research projects was suspended. This suspension by default resulted in some participants in a trial evaluating two versus three doses receiving only one dose. Since 2016, the successful introduction of HPV vaccination in immunisation programmes in Punjab and Sikkim (with high coverage and safety), government-sponsored opportunistic vaccination in Delhi, prospects of a single dose providing protection, and future availability of an affordable Indian vaccine shows promise for future widespread implementation and evaluation of HPV vaccination in India.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454